MicroRNA-18 facilitates the stemness of gastric cancer by downregulating HMGB3 though targeting Meis2

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Duraes C, Almeida GM, Seruca R, et al. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464(3):367–378.
   PubMed Web of Science ®Google Scholar
• Shan NL, Shin Y, Yang G, et al. Breast cancer stem cells: a review of their characteristics and the agents that affect them. Mol Carcinog. 2021;60(2):73–100.
   PubMed Web of Science ®Google Scholar
• Liu YC, Yeh CT, Lin KH, Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Cells, 2020. 9(6):1331.
   Google Scholar
• Brennecke J, Cohen SM. Towards a complete description of the microRNA complement of animal genomes. Genome Biol. 2003;4(9):228.
   PubMed Web of Science ®Google Scholar
• Vienberg S, Geiger J, Madsen S, et al. MicroRNAs in metabolism. Acta Physiol (Oxf). 2017;219(2):346–361.
   PubMed Web of Science ®Google Scholar
• Galagali H, Kim JK. The multifaceted roles of microRNAs in differentiation. Curr Opin Cell Biol. 2020; 67: 118–140.
   Google Scholar
• Li X, Zeng Z, Wang J, et al. MicroRNA-9 and breast cancer. Biomed Pharmacother. 2020;122:109687.
   PubMed Web of Science ®Google Scholar
• Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lieberman R, Pan J, et al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer. 2016;15(1):70.
   PubMedGoogle Scholar
• Zhao Q, Liu Y, Wang T, et al. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Eur J Pharmacol. 2020;884:173359.
   PubMed Web of Science ®Google Scholar
• Shi L, Xi J, Xu X, et al. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating beta-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed Pharmacother. 2019;109:902–909.
   PubMed Web of Science ®Google Scholar
• Wu ZH, Lin C, Liu -C-C, et al. MiR-616-3p promotes angiogenesis and EMT in gastric cancer via the PTEN/AKT/mTOR pathway. Biochem Biophys Res Commun. 2018;501(4):1068–1073.
   PubMed Web of Science ®Google Scholar
• Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer. 2009;101(4):707–714.
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada , H, Tatematsu, Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65(21):9628–9632.
   PubMed Web of Science ®Google Scholar
• Luo Z, Dai Y, zhang L, et al. miR-18a promotes malignant progression by impairing microRNA biogenesis in nasopharyngeal carcinoma. Carcinogenesis. 2013;34(2):415–425.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu H, Zhu J-M, et al. MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. J Gastroenterol Hepatol. 2016;31(1):155–163.
   PubMed Web of Science ®Google Scholar
• Liu P, Qi X, Bian C, et al. MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. Oncol Lett. 2017;13(6):4039–4046.
   PubMed Web of Science ®Google Scholar
• Wu CW, Dong Y-J, Liang Q-Y, et al. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One. 2013;8(2):e57036.
   PubMed Web of Science ®Google Scholar
• Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011;105(11):1733–1740.
   PubMed Web of Science ®Google Scholar
• Yao Y, Suo A-L, Li Z-F, et al. MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009;2(6):963–970.
   PubMed Web of Science ®Google Scholar
• Wang M, Wang, H, Wen, Y, et al. MEIS2 regulates endothelial to hematopoietic transition of human embryonic stem cells by targeting TAL1. Stem Cell Res Ther. 2018;9(1):340.
   PubMedGoogle Scholar
• Wang X, Ghareeb WM, Zhang Y, et al. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer. J Cell Physiol. 2019;234(10):18180–18191.
   PubMed Web of Science ®Google Scholar
• Schulte D, Frank D. TALE transcription factors during early development of the vertebrate brain and eye. Dev Dyn. 2014;243(1):99–116.
   PubMed Web of Science ®Google Scholar
• Guan L, Li T, Ai N, et al. MEIS2C and MEIS2D promote tumor progression via Wnt/beta-catenin and hippo/YAP signaling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):417.
   PubMed Web of Science ®Google Scholar
• Saghafinia S, Homicsko K, Di Domenico A, et al. Cancer cells retrace a stepwise differentiation program during malignant progression. Cancer Discov. 2021;11(10):2638–2657.
   PubMed Web of Science ®Google Scholar
• Fang J, Ge X, Xu W, et al. Bioinformatics analysis of the prognosis and biological significance of HMGB1, HMGB2, and HMGB3 in gastric cancer. J Cell Physiol. 2020;235(4):3438–3446.
   PubMed Web of Science ®Google Scholar
• Guo S, Wang Y, Gao Y, et al. Knockdown of high mobility group-Box 3 (HMGB3) expression inhibits proliferation, reduces migration, and affects chemosensitivity in gastric cancer cells. Med Sci Monit. 2016;22:3951–3960.
   PubMed Web of Science ®Google Scholar
• Guo X, Xiang C, Zhang Z, et al. Displacement of Bax by BMF mediates STARD13 3'UTR-Induced breast cancer cells apoptosis in an miRNA-depedent manner. Mol Pharm. 2018;15(1):63–71.
   PubMedGoogle Scholar
• Wang Y, Ji N, Zhou M, et al. [Construction and identification of recombinant lentivirus vector for microRNA-223 overexpression and suppression]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2015;33(5):451–455.
   PubMedGoogle Scholar
• Zheng L, Zhang Z, Zhang S, et al. RNA binding protein RNPC1 inhibits breast cancer cell metastasis via activating STARD13-Correlated ceRNA network. Mol Pharm. 2018;15(6):2123–2132.
   PubMedGoogle Scholar
• Brazvan B, Farahzadi R, Mohammadi SM, et al. Key immune cell cytokines affects the telomere activity of cord blood cells in vitro. Adv Pharm Bull. 2016;6(2):153–161.
   PubMedGoogle Scholar
• Hwang SS, Kim YU, Lee S, et al. Transcription factor YY1 is essential for regulation of the Th2 cytokine locus and for Th2 cell differentiation. Proc Natl Acad Sci U S A. 2013;110(1):276–281.
   PubMed Web of Science ®Google Scholar
• Liu C, Xing H, Guo C, et al. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Cell Cycle. 2019;18(18):2215–2227.
   PubMed Web of Science ®Google Scholar
• Muhammad N, Bhattacharya S, Steele R, et al. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 2016;7(36):58595–58605.
   PubMedGoogle Scholar
• Huang T, Wang G, Yang L, et al. Transcription factor YY1 modulates lung cancer progression by activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):947–958.
   PubMed Web of Science ®Google Scholar
• Yang F, Erhu, F, Hong, M, et al. Cis-acting circ-CTNNB1 promotes beta-catenin signaling and cancer progression via DDX3-Mediated transactivation of YY1. Cancer Res. 2019;79(3):557–571.
   PubMed Web of Science ®Google Scholar
• Zheng L, Guo, Q, Xiang, C, et al. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells. J Hematol Oncol. 2019;12(1):23.
   PubMed Web of Science ®Google Scholar
• Komatsu S, Ichikawa, D, Takeshita, H, et al. Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. Vivo. 2014;28(3):293–297.
   PubMed Web of Science ®Google Scholar
• Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 2010;1799(1–2):101–113.
   PubMed Web of Science ®Google Scholar
• Song N, Liu B, Wu J-L, et al. Prognostic value of HMGB3 expression in patients with non-small cell lung cancer. Tumour Biol. 2013;34(5):2599–2603.
   PubMedGoogle Scholar
• Waldum H, Fossmark R. Gastritis, Gastric Polyps and Gastric Cancer. Int J Mol Sci. 2021;22(12):6548.
   PubMed Web of Science ®Google Scholar
• Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442–4452.
   PubMed Web of Science ®Google Scholar
• Li L, Guo Z, Wang J, et al. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57(11):2910–2916.
   PubMed Web of Science ®Google Scholar
• Gao W, Shen H, Liu L, et al. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol. 2011;137(4):557–566.
   PubMed Web of Science ®Google Scholar
• Sanchez-Mejias A, Kwon, J, Chew, X, et al. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer. Int J Cancer. 2019;144(2):311–321.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang, L, Jiang, J, et al. The lncRNA SNHG15/miR-18a-5p axis promotes cell proliferation in ovarian cancer through activating Akt/mTOR signaling pathway. J Cell Biochem. 2020;121(12):4699–4710.
   PubMed Web of Science ®Google Scholar
• Bhanvadia RR, VanOpstall, C, Brechka, H, et al. MEIS1 and MEIS2 expression and prostate cancer progression: a role for HOXB13 binding partners in metastatic disease. Clin Cancer Res. 2018;24(15):3668–3680.
   PubMed Web of Science ®Google Scholar
• Jeong JH, Park, SJ, Dickinson, SI, et al. A constitutive intrinsic inflammatory signaling circuit composed of mir-196b, meis2, ppp3cc, and p65 drives prostate cancer castration resistance. Mol Cell. 2017;65(1):154–167.
   PubMed Web of Science ®Google Scholar
• Crijns AP, de Graeff P, Geerts D, et al. MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer. 2007;43(17):2495–2505.
   PubMed Web of Science ®Google Scholar
• Gu J, Xu, T, Huang, QH, et al. HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1alpha. Cancer Manag Res. 2019;11: 5075–5089.
   Google Scholar